Symptoms of hypoglycemia include shakiness, sweating, confusion, rapid heartbeat, irritability, and in severe cases, loss of consciousness
Early data from existing trials is promising, showing improvements in cardiovascular risk factors like blood pressure, lipid profiles, and inflammatory markers, but the definitive cardiovascular outcomes data is not yet available
If pancreatitis is suspected, discontinue tirzepatide and initiate appropriate management
Wegovy dosing schedule: Weeks 1-4: Starting dose 0.25 mg once weekly Weeks 5-8: 0.5 mg once weekly Weeks 9-12: 1 mg once weekly Weeks 13-16: 1.7 mg once weekly Weeks 17+: 1.7 or 2.4 mg once weekly The recommended maintenance dose of Wegovy in adults is 1.7 or 2.4 mg once weekly